サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1428487

欧州の核酸治療薬CDMO市場：分析と予測（2023年～2033年）

Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 104 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州の核酸治療薬CDMO市場：分析と予測（2023年～2033年）
出版日: 2024年02月20日
発行: BIS Research
ページ情報: 英文 104 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
主要市場統計
予測期間 2023年～2033年
2023年の評価額 12億7,000万米ドル
2033年予測 38億8,000万米ドル
CAGR 11.8%

欧州の核酸治療薬CDMOの市場規模は、2023年に12億7,000万米ドルとなりました。同市場は、2033年には38億8,000万米ドルに達すると予測され、予測期間の2023年～2033年のCAGRは11.80%になるとみられています。核酸治療薬CDMO市場は、慢性疾患や遺伝性疾患の治療における核酸治療薬の需要の増加、開発受託製造機関（CDMO）による製造プロセスの進歩、核酸治療薬のFDA承認の急増、CDMOの製造能力拡大への投資の増加など、さまざまな要因によって成長を遂げています。

欧州の核酸治療薬開発・製造受託機関（CDMO）市場は著しい成長を遂げています。この市場拡大の背景には、同地域で流行している慢性疾患や遺伝性疾患に対処するための核酸ベースの治療薬に対する需要の高まりがあります。さらに、CDMOによる製造プロセスの進歩は、核酸治療薬の生産効率と拡張性を高めています。また、この地域では、これらの治療薬に対するFDAの承認が増加しており、受容と採用が拡大していることを示しています。さらに、欧州全域でCDMO製造施設の拡張への投資が増加しており、市場の成長をさらに後押ししています。このようなダイナミックな情勢は、同地域のイノベーションとヘルスケアの進歩に対するコミットメントを強調するものであり、欧州を世界の核酸治療薬CDMO市場における主要参入国として位置づけています。

当レポートでは、欧州の核酸治療薬CDMO市場について調査し、市場の概要とともに、化学合成方法別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

第1章 市場

  • 市場の見通し
  • 業界の展望
  • COVID-19が核酸治療薬CDMOに与える影響
  • 現在の核酸治療用CDMOの情勢
  • 治療における核酸の重要な使用
  • 治療用に合成される核酸の種類
  • ビジネスダイナミクス

第2章 核酸治療薬CDMO市場（地域別）

  • 欧州の核酸治療薬CDMO市場
    • 主な調査結果
    • 市場力学
    • 市場規模と予測

第3章 市場-競合ベンチマーキングと企業プロファイル

  • 競合ベンチマーキング
    • 主要な戦略と展開
    • 市場シェア分析
    • 主要企業のビジュアルグラフィックス
  • 企業プロファイル
    • AGC Biologics
    • BACHEM
    • Eurofins Scientific
    • LGC Science Group Holdings Limited
    • Merck KGaA
図表

List of Figures

  • Figure 1: Services Offered by CDMOs
  • Figure 2: Europe Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 3: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
  • Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
  • Figure 5: Europe Nucleic Acid Therapeutics CDMO Market: Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
  • Figure 10: Core CDMO Services
  • Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
  • Figure 12: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
  • Figure 13: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
  • Figure 14: Synthesis Capabilities of Key Companies
  • Figure 15: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
  • Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
  • Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Purification
  • Figure 18: Factors considered while outsourcing to CDMO.
  • Figure 19: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 20: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
  • Figure 21: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Nucleic Acid Therapeutics CDMO Market, 2018-2020
  • Figure 22: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
  • Figure 23: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 24: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 25: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
  • Figure 26: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 27: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 28: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 29: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 30: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 31: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 32: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 33: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 34: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 35: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 36: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 37: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 38: Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
  • Figure 39: Funding Activities, January 2018-February 2023
  • Figure 40: New Offerings, January 2018-February 2023
  • Figure 41: Mergers and Acquisitions, January 2018-February 2023
  • Figure 42: Partnerships and Collaborations, January 2018-February 2023
  • Figure 43: Business Expansions, January 2018-February 2023
  • Figure 44: Regulatory and Legal Activities, January 2018-February 2023
  • Figure 45: Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
  • Figure 46: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
  • Figure 47: AGC Biologics: Product Portfolio
  • Figure 48: AGC Biologics: Overall Financials, $Million, 2019-2021
  • Figure 49: AGC Biologics: Segment Revenues, $Million, 2019-2021
  • Figure 50: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
  • Figure 51: BACHEM: Product Portfolio
  • Figure 52: BACHEM: Overall Financials, $Million, 2020-2022
  • Figure 53: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
  • Figure 54: BACHEM: Net Revenue (by Region), $Million, 2020-2022
  • Figure 55: BACHEM: R&D Expenditure, $Million, 2020-2022
  • Figure 56: Eurofins Scientific: Product Portfolio
  • Figure 57: Eurofins Scientific: Overall Financials, $Million, 2020-2022
  • Figure 58: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 59: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
  • Figure 60: LGC Science Group Holdings Limited: Product Portfolio
  • Figure 61: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
  • Figure 62: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
  • Figure 63: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
  • Figure 64: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
  • Figure 65: Merck KGaA: Product Portfolio
  • Figure 66: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 67: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 68: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
  • Figure 69: Merck KGaA: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
  • Table 2: Key Questions Answered in the Report
  • Table 3: Some of the Partnerships and Collaborations in the Nucleic Acid Therapeutics CDMO Market
  • Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
  • Table 5: Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
  • Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
  • Table 7: Advancements in Manufacturing Units of CDMO
  • Table 8: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
目次
Product Code: BHP1862SS

The Europe Nucleic Acid Therapeutics CDMO Market Expected to Reach $3.88 Billion by 2033

Introduction to Europe Nucleic Acid Therapeutics CDMO Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$1.27 Billion
2033 Forecast$3.88 Billion
CAGR11.8%

The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.

Market Introduction

The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

  • Solid-Phase Oligonucleotide Synthesis
  • Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • AGC Biologics
  • BACHEM
  • Eurofins Scientific
  • LGC Science Group Holdings Limited
  • Merck KGaA

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

  • 1.1 Market Outlook
    • 1.1.1 Market Overview
    • 1.1.2 Product Definition
    • 1.1.3 Inclusion and Exclusion Criteria
    • 1.1.4 Key Findings
  • 1.2 Industry Outlook
    • 1.2.1 Key Trends
      • 1.2.1.1 Significant Number of Collaborations among Market Players
      • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
      • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
    • 1.2.2 Opportunity Assessment
    • 1.2.3 Patent Analysis
      • 1.2.3.1 Awaited Technological Developments
      • 1.2.3.2 Patent Filing Trend (by Country)
      • 1.2.3.3 Patent Filing Trend (by Year)
    • 1.2.4 Production Capability
    • 1.2.5 Preferred Techniques By CDMO
      • 1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
      • 1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
      • 1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
    • 1.2.6 Factors Considered While Outsourcing To CDMO.
    • 1.2.7 Regulatory Framework
  • 1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO
    • 1.3.1 Pre-COVID-19 Phase
    • 1.3.2 During COVID-19
    • 1.3.3 Post-COVID-19 Phase
      • 1.3.3.1 Impact on Demand and Supply
  • 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
  • 1.5 Significant Usage of Nucleic Acid in Therapeutics
  • 1.6 Types of Nucleic Acid Synthesized for Therapeutics
    • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
    • 1.6.3 MicroRNAs (miRNAs)
    • 1.6.4 RNA Aptamers and RNA Decoys
    • 1.6.5 Ribozymes
    • 1.6.6 Circular RNAs
  • 1.7 Business Dynamics
    • 1.7.1 Impact Analysis
    • 1.7.2 Business Drivers
      • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
      • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
      • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
    • 1.7.3 Business Restraints
      • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
      • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
    • 1.7.4 Business Opportunities
      • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
      • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Nucleic Acid Therapeutics CDMO Market (by Region)

  • 2.1 Europe Nucleic Acid Therapeutics CDMO Market
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
      • 2.1.2.1 Impact Analysis
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
        • 2.1.3.2.1 Germany
          • 2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.2 U.K.
          • 2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.3 France
          • 2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.4 Spain
          • 2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.5 Italy
          • 2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 2.1.3.2.6 Rest-of-Europe
          • 2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Benchmarking
    • 3.1.1 Key Strategies and Developments
      • 3.1.1.1 Funding Activities
      • 3.1.1.2 New Offerings
      • 3.1.1.3 Mergers and Acquisitions
      • 3.1.1.4 Partnerships and Collaborations
      • 3.1.1.5 Business Expansions
      • 3.1.1.6 Regulatory and Legal Activities
    • 3.1.2 Market Share Analysis
    • 3.1.3 Visual Graphics of Key Companies
  • 3.2 Company Profile
    • 3.2.1 AGC Biologics
      • 3.2.1.1 Company Overview
      • 3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.1.3 Financials
      • 3.2.1.4 Recent Developments
      • 3.2.1.5 Analyst Perspective
    • 3.2.2 BACHEM
      • 3.2.2.1 Company Overview
      • 3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.2.3 Financials
      • 3.2.2.4 Recent Developments
      • 3.2.2.5 Analyst Perspective
    • 3.2.3 Eurofins Scientific
      • 3.2.3.1 Company Overview
      • 3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.3.3 Financials
      • 3.2.3.4 Recent Developments
      • 3.2.3.5 Analyst Perspective
    • 3.2.4 LGC Science Group Holdings Limited
      • 3.2.4.1 Company Overview
      • 3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.4.3 Recent Developments
      • 3.2.4.4 Analyst Perspective
    • 3.2.5 Merck KGaA
      • 3.2.5.1 Company Overview
      • 3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market
      • 3.2.5.3 Financials
      • 3.2.5.4 Recent Developments
      • 3.2.5.5 Analyst Perspective